Status:
COMPLETED
Long-Term Follow-up of Tandem High-Dose Therapy With Peripheral Blood Stem Cell for Adults With High-Risk Age-Adjusted IPI Aggressive Non-Hodgkin's Lymphomas
Lead Sponsor:
French Innovative Leukemia Organisation
Collaborating Sponsors:
Amgen
Conditions:
Lymphoma
Eligibility:
All Genders
15-60 years
Phase:
PHASE2
Brief Summary
Phase II multicenter pilot trial (073) evaluating tandem HDT with PBSC support in aa-IPI=3 untreated aggressive NHL.
Detailed Description
High-dose chemotherapy; untreated aggressive non-Hodgkin's lymphoma; high-risk; peripheral blood stem cell support Patients were aged from 15 to 60 years
Eligibility Criteria
Inclusion
- patients aged from 15 to 60 years
- previously untreated
- histologically proven aggressive NHL
- high aa-IPI (equal to 3)
- proper underlying organ function
Exclusion
- transformed low-grade, lymphoblastic, mantle-cell, or Burkitt's lymphoma
Key Trial Info
Start Date :
October 1 1994
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT00869284
Start Date
October 1 1994
End Date
February 1 2009
Last Update
March 25 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Emmanuel Gyan
Tours, France, 37000